F06.7
Conditions
Interventions
Group 1: Retrospective analysis of routine data from 1st of June 2023 and August 31, 2025
Sponsors
Charité-Universitätsmedizin
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Diagnoses of post-COVID syndrome (U09.9) or post-viral fatigue (G93.3) or myalgic encephalomyelitis/chronic fatigue syndrome (G93.3) 2. Presence of neurocognitive disorders (brain fog, memory, concentration, or word-finding difficulties) 3. Prescription of Ginkgo biloba at the first appointment 4. Age 18-65 years of any gender 5. Patients who attended their first and second appointments at the University Outpatient Clinic for Naturopathy and Prevention between June 1, 2023, and June 30, 2025 6. At least one follow-up appointment during or after taking Ginkgo biloba
Exclusion criteria
Exclusion criteria: Patients who do not fullfill inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Changes in neurocognitive symptoms, based on statements made by patients during medical interviews and a classification of symptoms on a three-point scale by the physician: o Deterioration o No change noticed o Slight improvement noticed o Significant improvement noticed | — |
Secondary
| Measure | Time frame |
|---|---|
| • Responders (noticed significant improvement vs. no significant improvement in neurocognitive symptoms) • Side effects of ginkgo biloba: occurrence and type of side effects or reasons for discontinuing ginkgo biloba • Use of new medications for fatigue or brain fog since baseline (e.g., antidepressants, aripiprazole, nootropics) | — |
Countries
Germany
Contacts
Public ContactBenno Brinkhaus
Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité Universitätsmedizin Berlin
Outcome results
None listed